Unlocking site potential — Engaging diverse populations and leveraging technology
Clinical sites are the backbone of trial execution. Accessing high-quality sites with diverse patients significantly increases the chances of shorter enrollment time, improves budgets, and helps with clinically sound findings. The growing pressure from stakeholders to speed the process of drug development has forced industry leaders to invest tremendous time and energy to try and identify how to maximize site potential and improve operational deliverables.
During this discussion, a panel of clinical experts will discuss the gaps in research today along with tactical solutions for:
Learning Objectives:
- Accessing and including diverse patient populations in upcoming trials
- The need for more technology options given the impact of COVID-19 on site research functions
- Key factors to consider when trying to expand the pool of patients engaged in clinical trials
Speakers
Robert Howal
US Site Partnership Manager
Sanofi
Background in ICU nursing. Over 23 years of industry experience within pharma, biotech, medical device, and CRO companies. Roles have included monitoring, clinical safety, training, study management, process improvement, and leadership. Passionate about building effective collaborative partnerships between sites, sponsors, patient advocacy groups, and vendors to expand access to clinical trials for all and to bring best in class new therapies to market as efficiently as possible.
Joscelyn Green
Cancer Research Manager
The Center for Cancer Prevention and Treatment
Joscelyn is an Oncology Certified Nurse with a Masters in Nursing Informatics obtained from Walden University. She has worked in clinical trials for 8 years in various therapeutic areas. Currently as Cancer Research Nurse Manager, along with her team; she works with cancer patients of all backgrounds and disease sites, providing them opportunities to participate in innovative clinical trials. After spending 3 years in cancer focused clinical trials, Joscelyn believes providing these opportunities at a community based hospital to increase access to the surrounding population is important work and vital to the future of cancer treatment. Most importantly, she believes in connecting to the heart beat of the people she is trying to help and promote an environment of care and understanding. Nominated for her institution’s Values in Action Award for Excellence this year, Joscelyn continuously strives to uphold that nomination by performing all duties and actions with excellence and reliability.
Liz Beatty
Chief Strategy Officer
Inato
Liz is a decisive leader with unparalleled expertise in the digital clinical trials space and a clear track record of leveraging technology to increase clinical trial participation and enhance the clinical trial experience for sites and patients. She plays an important role in delivering on Inato’s mission to bring advanced technology, new doctors and their patients into the clinical research ecosystem to unlock the potential of the many unengaged research sites.
